Innovative strategies for PBPC mobilization

Cytotherapy

Volumn 7, Issue 5, 2005, Pages 438-446

  Fruehauf, Stefan ^a   Seeger, T ^a   Topaly, J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

AMD3100; CXCR4; PBPC mobilization; SDF I

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3A; CTCE 0021; CTCE 0214; FLT3 LIGAND; INTEGRIN; LIGAND; PEPTIDE DERIVATIVE; PROTEINASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SB 290157; SELECTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; CELL TRANSFER; CELLULAR DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESEARCH; FLOW CYTOMETRY; HUMAN; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION;

EID: 27944455711     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240500319135     Document Type: Review

References (52)

1. Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 2003;102:1249-53.
2. Ho AD. Kinetics and symmetry of divisions of hematopoietic stem cells. Exp Hematol 2005;33:1-8.
3. Abkowitz JL, Catlin SN, McCallie MT, Guttorp P. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood 2002;100:2665-7.
4. Geiger H, Szilvassy SJ, Ragland P, van Zant G. Genetic analysis of progenitor cell mobilization by granulocyte colony-stimulating factor: verification and mechanisms for loci on murine chromosomes 2 and 11. Exp Hematol 2004;32:60-7.
5. Fruchauf S, Srbic K, Seggewiss R et al. Functional characterization of podia formation in normal and malignant hematopoietic cells. J Leukoc Biol 2002;71:425-32.
6. Levesque JP, Liu F, Simmons PJ et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004;104:65-72.
7. Semerad CL, Christopher MJ, Liu F et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; in press. [Epub ahead of print July 21, 2005: DOI 10.1182/blood-2004-01-0272].
8. Lopez A, Carion A, Herault O et al. In vitro trans-stromal migration of hematopoietic cells is increased after G-CSF-stimulation of human stromal cells [abstract 3110]. Blood 2003;102:837a-8a.
9. van Os R, Konings AW, Down JD. Compromising effect of low dose-rate total body irradiation on allogeneic bone marrow engraftment. Int J Radiat Biol 1993;64:761-70.
10. van Os R, Velders GA, Hagoort H et al. Protease inhibitors are involved in inhibition of stem cell mobilization induced by low dose irradiation [abstract 5317]. Blood 2003;102:397b.
11. Siczkowski M, Clarke D, Gordon MY. Binding of primitive hematopoietic progenitor cells to marrow stromal cells involves heparan sulfate. Blood 1992;80:912-9.
12. Spiegel A, Zcharia E, Goldshmidt O et al. Heparanase facilitates development and SDF-1 induced migration of hematopoietic stem and progenitor cells [abstract 3056]. Blood 2003;102:825a-6a.
13. + stem/progenitor cells to bone marrow. Blood 2004;103:2981-9.
14. Gotoh A, Ikebuchi K, Miyazawa K, Ohyashiki K. HMG-CoA reductase inhibitors (statins) suppress activation of rho and hematopoietic cell migration toward SDF-1 via suppression of geranylgeranylation [abstract 3063]. Blood 2003;102:827a.
15. Fukuda S, Broxmeyer HE, Pelus LM. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis. Blood 2005;105:3117-26.
16. Hayakawa J, Migita M, Fukazawa R et al. Pretreatment of donor mice with dextran sulfate enhances homing of hematopoietic stem cells [abstract 128]. Blood 2003;102:40a.
17. Gu Y, Filippi MD, Cancelas JA et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003;302:445-9.
18. Jansen M, Yang FC, Cancelas JA et al. Rac2-deficient hematopoietic stem cells show defective interaction with the hematopoietic microenvironment and long-term engraftment failure. Stem Cells 2005;23:335-46.
19. Papayannopoulou T, Priestley GV, Bonig H, Nakamoto B. The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization. Blood 2003;101:4739-47.
20. + progenitor cells. Blood 2004;103:4478-86.
21. Janowska-Wieczorek A, Majka M, Kijowski J et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001;98:3143-9.
22. Reca R, Mastellos D, Majka M et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 2003;101:3784-93.
23. Reca R, Kucia M, Wysoczynski M et al. Because moblized peripheral blood stem/progenitor cells are primed by various inflammatory molecules present in supernatants from leukapheresis products for their chemotactic responses to SDF-1 they engraft faster than bone marrow cells after transplantation [abstract 392]. Blood 2003;102:115a.
24. Wysoczynski M, Reca R, Ratajczak J et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 2005;105:40-8.
25. + hematopoietic cells: studies under flow conditions. Exp Hematol 2004;32:765-72.
26. Oelschlaegel U, Ehninger G, Kroschinsky F. Differences in expression of adhesion molecules in correlation to mobilisation efficacy in healthy stem cell donors investigated by flow cytometry [abstract]. Bone Marrow Trans 2004;33:560.
27. Christopherson KW, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 2003;101:4680-6.
28. -/- mice. Exp Hematol 2003;31:1126-34.
29. Christopherson KW, Hangoc G, Broxmeyer HE. Suppression or deletion of CD26 (DPPIV) activity on donor cells greatly enhances the efficiency of mouse hematopoietic stem and progenitor cell homing and engraftment in vivo [abstract 122]. Blood 2003;102:38a.
30. Selleri C, Montuori N, Ricci P et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 2005;105:2198-205.
31. Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-30.
32. Devine SM, Liu F, Holt M et al. AMD3100-mobilized murine hematopoietic stem cells and T-lymphocytes have identical capacity to induce multilineage stem cell engraftment, donor T-cell chimerism and GVHD in mice compared with G-CSF mobilized cells [abstract 3495]. Blood 2003;102:938a-9a.
33. Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201:1307-18.
34. + hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300.
35. Lack NA, Dale DC, Calandra GB et al. A pharmacokinetic/pharmacodynamic profile of the CXCR4 antagonist AMD3100 for the mobilization of hematopoietic progenitor cells [abstract 391]. Blood 2003;102:115a.
36. Lack NA, Green B, Dale DC et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34-hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 2005;77:427-36.
37. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-102.
38. Flomenberg N, Devine SM, Dipersio JF et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; in press May 12; [Epub ahead of print].
39. Fruehauf S, Seeger T, Topaly J et al. AMD3100 augments the number of mobilized peripheral blood progenitor cells (PBPC) when added to a G-CSF standard mobilization regime and AMD3100-mobilized PBPC result in rapid hematopoietic reconstitution after autologous transplantation. EBMT Meeting Prague February 2005; abstract 1035.
40. + targets for retroviral transduction results in high-level in vivo marking in rhesus macaques [abstract 5315]. Blood 2003;102:396b-7b.
41. + cells than G-CSF. Annual Meeting of the German Society for Hematology and Oncology (DGHO), 2005, abstract submitted.
42. + cells mobilized with the new CXCR4 antagonist AMD3100+G-CSF show increased anti-apoptotic, cell cycle, DNA repair and cell motility-associated gene expression when compared to G-CSF mobilization alone. Annual Meeting of the American Society for Hematology, 2005, abstract submitted.
43. Tudan C, Willick GE, Chahal S et al. C-terminal cyclization of an SDF-1 small peptide analogue dramatically increases receptor affinity and activation of the CXCR4 receptor. J Med Chem 2002;45:2024-31.
44. Zhong R, Law P, Wong D et al. Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells. Exp Hematol 2004;32:470-5.
45. + cells in synergy with cytokines [abstract 3576]. Blood 2003;102:960a. Abstract 3576.
46. Ames RS, Lee D, Foley JJ et al. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol 2001;166:6341-8.
47. Ratajczak J, Reca R, Kucia M et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 2004;103:2071-8.
48. Fukuda S, Bian H, King AG, Pelus LM. The accelerated engraftment of peripheral blood cell counts following transplantation with hematopoietic stem and progenitor cells (HSCs) mobilized by the CXC chemokine GROβT (CXCL2Δ4) is independent of homing to recipient bone marrow and the SDF-1α (CXCL12):CXCR4 migration axis [abstract 385]. Blood 2003;102:113a.
49. Pelus LM, Bian H, King AG. Alterations in the stoichiometry and kinetics between matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) are responsible for the synergistic mobilization of peripheral blood hematopoietic stem cells (HSC) by the CXC chemokine GROβT/CXCL2Δ4 plus G-CSF [abstract 2572]. Blood 2003;102:694a-5a.
50. Pelus LM, Bian H, King AG, Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2-delta4. Blood 2004;103:110-9.
51. Fruehauf S, Haas R, Conradt C et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995;85:2619-26.
52. Fruehauf S, Schmitt K, Veldwijk MR et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999;105: 786-94.